ZURICH, Switzerland, Dec. 20 /PRNewswire/ -- In a press release published
this evening, Sulzer AG announced legal steps to be taken against one-time
subsidiary Sulzer Medica. This action represents no new development.
Dr. Stephan Rietiker, CEO of Sulzer Medica, commented on the action of
Sulzer AG by saying: "It is our clear intent to quickly and fairly compensate
any affected patients in the USA. We will not be deterred from this path by
third parties. Sulzer AG remains welcome to participate in the settlement."
Sulzer Medica's subsidiary companies develop, produce, and distribute
medical implants and biological materials for cardiovascular and orthopedic
markets worldwide. The product array includes artificial joint, vertebral,
and dental implants, trauma products, heart valves, synthetic blood vessels
and stents for vascular and non-vascular obstructions. (Swiss Stock Market
symbol: SMEN, New York Stock Exchange symbol: SM).
THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION
REFORM ACT 1995
This report contains forward-looking statements including, but not limited
to, projections of future performance of materials and products, financial
conditions, results of operations and cash flows, containing risks and
uncertainties. These statements are subject to change based on known risks
detailed from time to time in the Company's Securities and Exchange Commission
filings and other known and unknown risks and various other factors which
could cause the actual results or performance to differ materially from the
statements made herein.
This news release is available on the Internet at:
http://www.sulzermedica.com. The company's quarterly report is available on
the Sulzer Medica corporate web site at http://www.sulzermedica.com
"Investors" / "Financial reports".
SOURCE Sulzer Medica
/CONTACT: Beatrice Tschanz, +41-1-308-38-66, or fax, +41-1-308-35-06, or
Andy Bantel, +41-1-308-37-69, or mobile, +41-79-231-56-62, or fax,
+41-1-308-35-06, or firstname.lastname@example.org, both of Sulzer Medica
Corp. Communications; or Investors, Michael Staheli, +41-1-308-38-64, or fax,
+41-1-308-35-08, or email@example.com, or U.S., Jim Johnson,
+1-713-561-6376, or fax, +1-713-561-6380, or
firstname.lastname@example.org, both of Sulzer Medica/
/Web site: http://www.sulzermedica.com /
CO: Sulzer Medica; Sulzer AG
IN: HEA MTC
-0- Dec/20/2001 19:52 GMT
Press spacebar to pause and continue. Press esc to stop.